PremiumCompany AnnouncementsCardiol Therapeutics Advances Heart Disease Treatments with Promising Clinical Results CRDL Earnings Report this Week: Is It a Buy, Ahead of Earnings? Cardiol Therapeutics Schedules Annual General Meeting for May 2025 PremiumThe FlyCardiol Therapeutics initiated with a Buy at Rodman & Renshaw Cardiol Therapeutics Reports Promising Phase II Results Cardiol Therapeutics Faces Rising Losses and Falling Assets PremiumCompany AnnouncementsCardiol Therapeutics Secures $13.5M in Public Offering Cardiol Therapeutics 8.44M share Secondary priced at $1.60 Cardiol Therapeutics Sets Common Share Offering Price 
